Exploring the remarkable biological properties of this prenylated flavonoid from hop cones
Xanthohumol (Xn) is a prenylated chalcone, a specific type of flavonoid characterized by the presence of a prenyl group (isoprenoid) in its molecule 7 . This group is largely responsible for its exceptional biological activity. Naturally, Xn is produced in the resin glands of hop cones, where it can constitute up to 1% of dry mass 1 5 .
Although beer is the most common dietary source of xanthohumol, its content in traditionally brewed beer is unfortunately very low - ranging from just 2 μg/L to 1.2 mg/L 7 . This is because the unstable chalcone structure is converted during brewing (under the influence of heat and pH change) to isoxanthohumol, a flavanone with different properties 1 5 .
Preclinical studies conducted in vitro (on cell cultures) and in vivo (on animal models) have revealed an extremely wide spectrum of xanthohumol activity.
Xn is intensively studied as a potential chemotherapeutic agent. It has been shown to inhibit the proliferation of cancer cells, induce their apoptosis and hinder angiogenesis 9 .
Xanthohumol shows beneficial effects in obesity, type 2 diabetes and lipid disorders. It can inhibit the differentiation of preadipocytes into mature fat cells and improve insulin sensitivity 5 .
As a phenolic compound, Xn neutralizes harmful free radicals 2 .
Reduces levels of pro-inflammatory cytokines 2 .
Shows activity against bacteria and fungi 1 .
Traditional extraction of Xn from hops is dependent on agricultural factors and can burden the environment. Therefore, Chinese scientists have developed a revolutionary method of de novo biosynthesis of xanthohumol in Saccharomyces cerevisiae yeast 3 .
A set of genes from hops and other organisms encoding enzymes necessary for xanthohumol production were introduced into the yeast genome. The pathway was divided into four modules:
To increase efficiency, the team applied a series of engineering strategies:
Through these treatments, scientists managed to achieve an 83-fold increase in demethylxanthohumol (DMX) production, a direct precursor of Xn, to a level of 4.0 mg/L in modified yeast 3 .
| Yeast Strain | DMX Concentration | Relative Increase |
|---|---|---|
| YS103 | Not detected | - |
| YS107 | Not detected | - |
| YS116 | 12 μg/L | - |
| YS117 | 104 μg/L | 7.7x |
| Final Strain | 4000 μg/L | 83x (vs YS116) |
| Tool/Technique | Application |
|---|---|
| Liquid Chromatography (UPLC) | Isolation and analysis of xanthohumol |
| GC-MS | Analysis of hop essential oil composition |
| UHPSFC | Quantitative determination of prenylated components |
| EPR Spectroscopy | Assessment of antioxidant potential |
| HPTLC-EDA Tests | Rapid screening of biological activity |
Despite enormous potential, xanthohumol has a serious drawback - very low bioavailability. It is poorly soluble in water, and after oral administration it is poorly absorbed from the gastrointestinal tract and quickly metabolized. Its bioavailability in rats is estimated at only 0.5-1.2% 6 .
To overcome this limitation, scientists are developing advanced drug delivery systems. One of the most promising strategies is encapsulation of xanthohumol in biodegradable polymers. For this purpose, the following are created:
Such "transport boxes" protect the Xn molecule, increase its solubility and facilitate penetration into cells, significantly increasing therapeutic efficacy 1 .
Promising laboratory results raise the question of the safety of xanthohumol use in humans. A randomized, triple-blind, placebo-controlled phase I clinical trial provides the answer.
Xanthohumol at this dose was safe and well tolerated. No clinically significant changes in laboratory parameters or differences in quality of life compared to the placebo group were noted. There were also no serious adverse events, confirming that Xn is suitable for further, more advanced clinical trials 2 .
Xanthohumol is a fascinating example of how nature can still surprise. A compound that for decades was merely a component of beer bitterness turns out to have enormous therapeutic potential.
Work on improving its bioavailability using advanced polymer carrier systems and revolutionary achievements in the field of biotechnology and metabolic engineering, enabling its synthesis in yeast, are bringing us closer to the moment when xanthohumol may become a valued ingredient in drugs, dietary supplements and functional foods.
Hops, which for centuries have served entertainment, may in the future also enrich our health.
Potential ingredient in cancer and metabolic disease therapies
Dietary supplements with antioxidant and anti-inflammatory properties
Enhanced beers and other products with health benefits